Anja Schiel has studied Biology at the Johannes Gutenberg-University, Mainz, Germany. She received her PhD from the Free University in Amsterdam in 2006 and worked several years as Post-Doc on a range of subjects focusing on oncology, immunology and molecular biology, first at the University of Leiden and later at the University of Oslo, before starting at the Norwegian Medical Products Agency (NOMA) in 2012.
At NOMA she is working as Special Adviser/Statistician/Methodologist both on regulatory and HTA projects. She has been Chair of EMA’s Biostatistics Working Party (2017 – 2019) and during 2019 – 2022 she was Chair of EMA’s Scientific Advice Working Party (SAWP). She continues currently as alternate member at the SAWP and is member of the recently established Methodology Working Party (MWP) at EMA.
She has been involved in EUnetHTA JA3 and its successor, EUnetHTA 21, with particular focus on parallel EMA-HTA scientific advice (joined scientific consultations). As one of the vice Chairs of the JSC Committee for Scientific Consistency and Quality (JSC CSCQ) she was involved in the preparation of the implementation of developer support under the Regulation on Health Technology Assessment (HTAR, to apply from January 12th 2025). Until January 2025 she was a member of the HTA coordination groups (HTACG) Joined Scientific consultation
